These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8045141)

  • 1. An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody.
    Kett DH; Quartin AA; Sprung CL; Fisher CJ; Peña MA; Heard SO; Zimmerman JL; Albertson TE; Panacek EA; Eidelman LA
    Crit Care Med; 1994 Aug; 22(8):1227-34. PubMed ID: 8045141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
    Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
    N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.
    McCloskey RV; Straube RC; Sanders C; Smith SM; Smith CR
    Ann Intern Med; 1994 Jul; 121(1):1-5. PubMed ID: 8198341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A controlled trial of HA-1A in a canine model of gram-negative septic shock.
    Quezado ZM; Natanson C; Alling DW; Banks SM; Koev CA; Elin RJ; Hosseini JM; Bacher JD; Danner RL; Hoffman WD
    JAMA; 1993 May; 269(17):2221-7. PubMed ID: 8474201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels.
    Wortel CH; von der Möhlen MA; van Deventer SJ; Sprung CL; Jastremski M; Lubbers MJ; Smith CR; Allen IE; ten Cate JW
    J Infect Dis; 1992 Dec; 166(6):1367-74. PubMed ID: 1431255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin.
    Luce JM
    Crit Care Med; 1993 Aug; 21(8):1233-41. PubMed ID: 8339592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of clinical study design on cost-effectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody.
    Linden PK; Angus DC; Chelluri L; Branch RA
    J Crit Care; 1995 Dec; 10(4):154-64. PubMed ID: 8924965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Projected impact of monoclonal anti-endotoxin antibody therapy.
    Bates DW; Lee TH
    Arch Intern Med; 1994 Jun; 154(11):1241-9. PubMed ID: 8203991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human monoclonal antibody against endotoxin.
    Zarowitz BJ
    DICP; 1991; 25(7-8):778-83. PubMed ID: 1949939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group.
    Bone RC; Balk RA; Fein AM; Perl TM; Wenzel RP; Reines HD; Quenzer RW; Iberti TJ; Macintyre N; Schein RM
    Crit Care Med; 1995 Jun; 23(6):994-1006. PubMed ID: 7774238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI.
    Rogy MA; Moldawer LL; Oldenburg HS; Thompson WA; Montegut WJ; Stackpole SA; Kumar A; Palladino MA; Marra MN; Lowry SF
    Ann Surg; 1994 Jul; 220(1):77-85. PubMed ID: 8024362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preventive interruption of the administration of HA-1A monoclonal antibody against endotoxin].
    Torrabadella de Reynoso P; Trilla A; Salgado A; Ribas J
    Med Clin (Barc); 1993 Apr; 100(13):518. PubMed ID: 8479241
    [No Abstract]   [Full Text] [Related]  

  • 13. [Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients].
    Costongs LG; Speelman P; van Lieshout JJ; van Deventer SJ; Lubbers MJ; Schipper HG
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):355-60. PubMed ID: 8437634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy of gram-negative sepsis: use of monoclonal antibodies to lipopolysaccharide.
    Fink MP
    Crit Care Med; 1993 Feb; 21(2 Suppl):S32-9. PubMed ID: 8428494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunotherapy using the anti-endotoxin antibody HA-1A in patients with sepsis syndrome; good results in relation to treatment with placebo].
    Wortel CH; von der Möhlen MA; van Deventer SJ; Schipper HG; Lorijn RH; ten Cate JW
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):350-4. PubMed ID: 8437633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome.
    Fisher CJ; Zimmerman J; Khazaeli MB; Albertson TE; Dellinger RP; Panacek EA; Foulke GE; Dating C; Smith CR; LoBuglio AF
    Crit Care Med; 1990 Dec; 18(12):1311-5. PubMed ID: 2245602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HA-1A in septic patients with ARDS: results from the pivotal trial.
    Bigatello LM; Greene RE; Sprung CL; Panacek EA; Straube RC; Zimmerman JL; Maunder RJ; Lanken PN; Pile-Spellmann E; Stanek KS
    Intensive Care Med; 1994 May; 20(5):328-34. PubMed ID: 7930026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group.
    Dhainaut JF; Tenaillon A; Hemmer M; Damas P; Le Tulzo Y; Radermacher P; Schaller MD; Sollet JP; Wolff M; Holzapfel L; Zeni F; Vedrinne JM; de Vathaire F; Gourlay ML; Guinot P; Mira JP
    Crit Care Med; 1998 Dec; 26(12):1963-71. PubMed ID: 9875905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of N-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients: results from a prospective, randomized, double-blind study.
    Spies CD; Reinhart K; Witt I; Meier-Hellmann A; Hannemann L; Bredle DL; Schaffartzik W
    Crit Care Med; 1994 Nov; 22(11):1738-46. PubMed ID: 7956276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.